We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+19.33%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.67B
AUM Growth
+$125M
Cap. Flow
+$47M
Cap. Flow %
1.76%
Top 10 Hldgs %
52.29%
Holding
77
New
9
Increased
18
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$132M
2
ARGX icon
argenx
ARGX
+$78.1M
3
IMA
ImageneBio Inc
IMA
+$45.7M
4
CGEM icon
Cullinan Oncology
CGEM
+$42.6M
5
MRUS
Merus
MRUS
+$34.1M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$101M
2
AMRN
Amarin Corp
AMRN
+$60.8M
3
XNCR icon
Xencor
XNCR
+$55.2M
4
ALXO icon
ALX Oncology
ALXO
+$46.6M
5
RCUS icon
Arcus Biosciences
RCUS
+$30.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.46%
2 Financials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
26
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$28.6M 1.07%
3,094,174
+2,600,657
+527% +$27.1M
VSTM icon
27
Verastem
VSTM
$496M
$28.4M 1.06%
956,750
+25,000
+3% +$700K
INFI
28
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$27.1M 1.02%
8,383,645
-9,043,323
-52% -$30.2M
OVID icon
29
Ovid Therapeutics
OVID
$420M
$25.8M 0.97%
6,417,551
+1,895,500
+42% +$6.3M
ANAB icon
30
AnaptysBio
ANAB
$1.56B
$25.6M 0.96%
+1,189,500
New +$30M
FBRX icon
31
Forte Biosciences
FBRX
$1.57B
$24.6M 0.92%
28,752
– –
CALT
32
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$20.7M 0.78%
750,000
– –
CTIC
33
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$20.2M 0.76%
6,929,690
– –
STRO icon
34
Sutro Biopharma
STRO
$403M
$18.8M 0.71%
82,683
-102,733
-55% -$24.4M
IMVT icon
35
Immunovant
IMVT
$7.86B
$18.4M 0.69%
1,144,016
+629,646
+122% +$16.6M
CFRX
36
DELISTED
ContraFect Corporation
CFRX
$18.3M 0.69%
47,654
+27,654
+138% +$11.9M
GRTS
37
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$17.6M 0.66%
1,861,239
-834,179
-31% -$11.5M
SLN
38
Silence Therapeutics
SLN
$527M
$15.8M 0.59%
+666,666
New +$16.2M
ELTX icon
39
Elicio Therapeutics
ELTX
$74.1M
$15.8M 0.59%
+87,500
New +$16.9M
PVLA
40
Palvella Therapeutics
PVLA
$2.04B
$14.1M 0.53%
68,682
– –
REPL icon
41
Replimune Group
REPL
$900M
$14.1M 0.53%
+461,428
New +$17.3M
CALA
42
DELISTED
Calithera Biosciences, Inc
CALA
$13.5M 0.51%
278,335
+60,273
+28% +$3.51M
COGT icon
43
Cogent Biosciences
COGT
$6.72B
$13.5M 0.5%
1,532,282
– –
LITS
44
Lite Strategy Inc
LITS
$32.8M
$12.3M 0.46%
179,408
-23,050
-11% -$1.61M
ELDN icon
45
Eledon Pharmaceuticals
ELDN
$259M
$11.9M 0.45%
1,113,435
+350,156
+46% +$5.28M
GNCA
46
DELISTED
Genocea Biosciences, Inc.
GNCA
$10.9M 0.41%
4,012,404
– –
RNAC icon
47
Cartesian Therapeutics
RNAC
$222M
$10.8M 0.4%
79,333
-30,832
-28% -$3.83M
AMRN
48
Amarin Corp
AMRN
$295M
$10.7M 0.4%
85,799
-452,281
-84% -$60.8M
CDTX
49
DELISTED
Cidara Therapeutics
CDTX
$9.95M 0.37%
186,985
– –
CRVS icon
50
Corvus Pharmaceuticals
CRVS
$1.1B
$9.95M 0.37%
3,229,426
+1,285,714
+66% +$4.64M
1
2
3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2021 Portfolio in Review

As of Q1 2021, BVF Inc held 77 positions worth $2.67B, up 4.9% from $2.54B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

BVF Inc's Q1 2021 filing shows 9 new, 18 increased, 19 reduced and 10 closed positions. Its largest new stake was ImageneBio Inc: 133,305 shares worth $45.2M. The largest sale was Cytokinetics, an estimated $101M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

  • BVF Inc's largest Q1 2021 buy was ImageneBio Inc: 133,305 shares worth $45.2M.
  • BVF Inc added most to Five Prime Therapeutics, Inc. in Q1 2021, an estimated $132M increase.
  • BVF Inc's biggest Q1 2021 reduction was Amarin Corp, cutting an estimated $60.8M.
  • BVF Inc fully exited Cytokinetics in Q1 2021, selling an estimated $101M.
  • BVF Inc's ten largest holdings make up 52% of its $2.67B portfolio in Q1 2021.
  • BVF Inc opened 9 new positions and closed 10 in Q1 2021.
  • BVF Inc's portfolio value rose 4.9% quarter-over-quarter to $2.67B.

Based on BVF Inc's 13F filing for Q1 2021, filed 17 May 2021.